SCOTTSDALE, Ariz., July 02, 2018 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC:INLB) (“Item 9 Labs”), a leading provider of cannabis health solutions for the modern consumer, announced that Sara Gullickson has been appointed as president of Item 9 Labs. Through the development of innovative lifestyle products and proprietary delivery platforms, Gullickson will oversee Item 9 Labs Licensing Application and Acquisition Strategy.
Named one of the Top Ten Cannabis Entrepreneurs in the nation by Herb Magazine, Gullickson is an internationally recognized industry expert. Founder and CEO of Dispensary Permits, Gullickson brings over 8 years of experience in executive level roles. She will lead overall compliance, distribution and quality control for cultivation and production, and development of aggressive growth strategies with Bryce Skalla, CEO of Item 9 Labs.
“I am delighted that Sara will lead Item 9 into its next stage of growth. She has been involved in the cannabis industry since its inception and has played an instrumental role in raising medical marijuana awareness. As an established industry advocate, along with her past contributions and continued vision, we are confident that our expansion into the high-growth Cannabis Bio-Medical market will continue to be successful,” stated Skalla.
Gullickson established her existing cannabis consulting firm Dispensary Permits in 2010, securing multiple cannabis license wins across 13 competitive state markets. Her operational and dispensary opening experience extends throughout North America, and includes consulting projects in Europe, South America, and New Zealand, regarding the implementation of new programs.
“As the industry evolves many brands are becoming multi-market operators, its only a natural progression for our firm to represent both local entrepreneurs and national cannabis companies with applications and license acquisitions,” Gullickson noted.
With Gullickson at the helm, Item 9 Labs will bring a balanced approach to a nuanced market, focusing on patients and wellness, “I’m thrilled to take on this leadership role and work closely with a company that aligns with my values and ethics. We both are dedicated to building quality and integrity within the cannabis community,” she announced.
Gullickson’s market foresight and expertise was a key draw for Item 9 Labs ultimate expansion goals. “I’ve built dozens of state-specific best practices for entrepreneurs to run compliant facilities. Now we get to take those resources and blend them with Item 9’s distinct culture, mission, and vision for the cannabis market,” said Gullickson.
The evolving industry has transitioned from broad to niche business strategies, “It’s not about producing a road-map or a ‘seed to sale’ model anymore, it’s about incorporating individual best practices and company vision into specific markets for all the seasons of cannabis,” Gullickson explained.
Gullickson has presented at the 2018 Real Estate Wealth Expo in Toronto, the 2018 World Medical Cannabis Conference in Pittsburgh, the 2017 Real Estate Wealth Expo in Los Angeles, and the Cannabis World Congress and Business Expo. This August, she will speak at MJBizCon International in Toronto.
About Item 9 Labs Corp.: Item 9 Labs Corp. (OTC:INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern Cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com .
Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Media Contact: Investor Relations: Jeffrey Rassás (480)463-4246 or (877)876-4868 Email: jeffrey@airwarelabs.com
Investor Contact: Scott Eckstein KCSA Strategic Communications seckstein@kcsa.com 212-896-1210
